Company intelligence / Profile preview

Cellectar Biosciences

Florham Park, New Jersey, United Statescellectar.com ↗

Ownership: Public · CLRB
Development stage: Phase 2

Overview

The company's lead asset iopofosine I 131 is being evaluated in Phase 2b studies for relapsed/refractory multiple myeloma and CNS lymphoma, as well as in a pivotal expansion cohort in relapsed/refractory WM patients. The company is also conducting a Phase 1b CLOVER-2 study for pediatric patients with high-grade gliomas. Recent data from the CLOVER-WaM Phase 2 clinical trial was presented at ASH 2024. In December 2024, the company announced a strategic restructuring to focus on advancing its radiotherapeutic assets. As of April 30, 2025, the company announced plans to explore strategic alternatives.

Therapeutic areas: Oncology
Modalities: RadiotherapeuticsPhospholipid Drug Conjugates
Industry: Biotech

Drug pipeline

13 assets

Iopofosine I-131

12 more assets in the full pipeline.

Partnerships

Multiple partnered PDC assets (specific partners not named)

Financials

Market cap: $10.9M
Total revenue: $0
Enterprise value: $-21.6M

Beyond the preview

Go deeper on Cellectar Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellectar Biosciences.